Breaking News, Collaborations & Alliances

MEDI&GENE Enters Catalyze Agreement with Lilly to Advance Obesity Therapeutic

Brings Lilly’s expertise in molecule engineering and development to MEDI&GENE’s asset.

Author Image

By: Charlie Sternberg

Associate Editor

MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, has entered into a Catalyze agreement with Eli Lilly and Company (Lilly) to advance a next-generation therapeutic for obesity. Under the agreement, Lilly ExploR&D will bring Lilly’s expertise in molecule engineering and development to a MEDI&GENE asset, with the goal to advance the program to clinical trial readiness. Lilly ExploR&D is part of the Lilly Catalyze360 suite of offerings d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters